BioWorld Asia

Oct. 5, 2005

Scientists Probe Signature' Of Cancer Genetic Damage

NatImmune, Enzon Enter Deal On Recombinant MBL

Closing In On First Revenues, Phoqus Seeking IPO On Aim

MMI Raises £10M For Genvax's Clinical Studies Of Vaccines

Other News To Note

Karo Bio Seeking SEK280M In Discounted Rights Issue

Karo Bio AB is seeking SEK280 million (US$35.9 million) in a discounted rights issue to fund its switch from early stage discovery to clinical development. (BioWorld International) Read More

SkyePharma Raising Funds After Scuttled Partner Deal

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...